Literature DB >> 2806134

Treatment of the anaemia of chronic renal failure with recombinant human erythropoietin.

C G Winearls1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2806134     DOI： 10.2165/00003495-198938030-00002

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  28 in total

1.  Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial.

Authors:  V S Lim; R L DeGowin; D Zavala; P T Kirchner; R Abels; P Perry; J Fangman
Journal:  Ann Intern Med       Date:  1989-01-15       Impact factor: 25.391

2.  Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells.

Authors:  M Takeuchi; S Takasaki; H Miyazaki; T Kato; S Hoshi; N Kochibe; A Kobata
Journal:  J Biol Chem       Date:  1988-03-15       Impact factor: 5.157

3.  Cloning and expression of the human erythropoietin gene.

Authors:  F K Lin; S Suggs; C H Lin; J K Browne; R Smalling; J C Egrie; K K Chen; G M Fox; F Martin; Z Stabinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

4.  Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity.

Authors:  R Swartz; J Dombrouski; M Burnatowska-Hledin; G Mayor
Journal:  Am J Kidney Dis       Date:  1987-03       Impact factor: 8.860

5.  Erythropoietin alert: risks of high hematocrit hemodialysis.

Authors:  J H Shinaberger; J H Miller; P W Gardner
Journal:  ASAIO Trans       Date:  1988 Jul-Sep

6.  Characterization and biological effects of recombinant human erythropoietin.

Authors:  J C Egrie; T W Strickland; J Lane; K Aoki; A M Cohen; R Smalling; G Trail; F K Lin; J K Browne; D K Hines
Journal:  Immunobiology       Date:  1986-09       Impact factor: 3.144

7.  Effect of treatment with recombinant human erythropoietin on peripheral hemodynamics and oxygenation.

Authors:  B Nonnast-Daniel; A Creutzig; K Kühn; J Bahlmann; E Reimers; R Brunkhorst; L Caspary; K M Koch
Journal:  Contrib Nephrol       Date:  1988       Impact factor: 1.580

8.  Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anaemias.

Authors:  J C Schooley; B Kullgren; A C Allison
Journal:  Br J Haematol       Date:  1987-09       Impact factor: 6.998

9.  Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.

Authors:  C G Winearls; D O Oliver; M J Pippard; C Reid; M R Downing; P M Cotes
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

10.  Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis.

Authors:  S Casati; P Passerini; M R Campise; G Graziani; B Cesana; M Perisic; C Ponticelli
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-24
View more
  3 in total

Review 1.  Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis.

Authors:  D Faulds; E M Sorkin
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

2.  Potential of Novel EPO Derivatives in Limb Ischemia.

Authors:  Dhiraj Joshi; Janice Tsui; Rebekah Yu; Xu Shiwen; Sadasivam Selvakumar; David J Abraham; Daryll M Baker
Journal:  Cardiol Res Pract       Date:  2012-02-22       Impact factor: 1.866

3.  The effect of recombinant human erythropoietin treatment on tumour radiosensitivity and cancer-associated anaemia in the mouse.

Authors:  B Joiner; V K Hirst; S R McKeown; J J McAleer; D G Hirst
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.